Overview

T-705a Multicenter Study in Adults Subjects With Uncomplicated Influenza

Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
This is safety and pharmacokinetics (PK) of favipiravir study in adults 18-80 years of age diagnosed with uncomplicated influenza.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
MDVI, LLC
Collaborator:
United States Department of Defense
Treatments:
Favipiravir